Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug
Background: The World Health Organization Global Tuberculosis Report 2021 defines tuberculosis as the second infectious disease that causes sickness and death after COVID 19 and ranks it as the 13th among the global causes of death. However, the prevalence of the patients developing a hypersensitivi...
Main Authors: | Zeynep Yegin Katran, Ismet Bulut, Aylin Babalik, Metin Keren |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | International Journal of Mycobacteriology |
Subjects: | |
Online Access: | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2022;volume=11;issue=3;spage=309;epage=317;aulast=Katran |
Similar Items
-
Tuberculosis treatment-related lichenoid drug eruptions
by: Zeynep Yegin Katran, et al.
Published: (2022-01-01) -
CNS tuberculoma in an immunocompetent patient: A case report of multi-drug hypersensitivity to RIPE therapy
by: Benjamin Huber, et al.
Published: (2023-01-01) -
Drug hypersensitivity in drug-resistant tuberculosis
by: Zeynep Yegin Katran, MD, et al.
Published: (2023-05-01) -
A case report and systematic literature review: insulin-induced type III hypersensitivity reaction
by: Rebecca R. Meredith, et al.
Published: (2024-02-01) -
The phenotypically quantitative nature of hypersensitivity of European plum (Prunus domestica L.) against the Plum pox virus and its description using the hypersensitivity index
by: M. Neumüller, et al.
Published: (2008-06-01)